SCHEMBL30453373

SCHEMBL30453373

Nc1ncc(-c2cccnc2)cc1OCc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 5/20 0.63
CYP11B2 P19099 5/20 0.63
CYP19A1 P11511 3/20 0.63
MAP4K4 O95819 1/20 0.62
LTA4H P09960 1/20 0.56
MAPK14 Q16539 1/20 0.56
MAP4K3 Q8IVH8 2/20 0.53
PDPK1 O15530 1/20 0.50
IKBKB O14920 2/20 0.49
JAK2 O60674 2/20 0.48
MET P08581 1/20 0.46
HTR1A P08908 1/20 0.46
DRD2 P14416 1/20 0.46
ALDH1A1 P00352 1/20 0.45
POLB P06746 1/20 0.45
MAPK1 P28482 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL488124 1.00 CYP11B1 (0.63) CYP11B1CYP11B2CYP19A1MAP4K4LTA4H
SCHEMBL488178 0.89 MAP4K4 (0.75) CYP11B1CYP11B2CYP19A1MAP4K4LTA4H
SCHEMBL488296 0.88 MAP4K3 (0.52) CYP11B1CYP11B2CYP19A1MAP4K4LTA4H
SCHEMBL30453298 0.88 MAP4K3 (0.52) CYP11B1CYP11B2CYP19A1MAP4K4LTA4H
SCHEMBL487829 0.86 MAP4K4 (0.64) CYP11B1CYP11B2CYP19A1MAP4K4LTA4H
SCHEMBL14259206 0.84 CYP11B1 (0.63) CYP11B1CYP11B2CYP19A1MAP4K4LTA4H
SCHEMBL30453947 0.83 MAP4K4 (0.68) CYP11B1CYP11B2CYP19A1MAP4K4LTA4H
SCHEMBL487917 0.83 MAP4K4 (0.68) CYP11B1CYP11B2CYP19A1MAP4K4LTA4H
SCHEMBL30454968 0.82 MAP4K3 (0.54) CYP11B1CYP11B2CYP19A1MAP4K4MAP4K3
SCHEMBL488416 0.82 MAP4K3 (0.54) CYP11B1CYP11B2CYP19A1MAP4K4MAP4K3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113181362-B Medicament for preventing and/or treating amyotrophic lateral sclerosis 国立大学法人京都大学 2023-06-13 CN disclosed